Corvus Pharmaceuticals, Inc. Payments to Acquire Available-for-sale Securities
Corvus Pharmaceuticals, Inc. (CRVS) reported Payments to Acquire Available-for-sale Securities of $88.31 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-03-01
- Corvus Pharmaceuticals, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $13.24M, a 85.85% decline year-over-year.
- Corvus Pharmaceuticals, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $28.00M, a 133.67% increase year-over-year.
- Corvus Pharmaceuticals, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-06-30 was $29.06M, a 52.87% decline year-over-year.
- Corvus Pharmaceuticals, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-03-31 was $18.01M, a 80.24% decline year-over-year.
- Corvus Pharmaceuticals, Inc. payments to acquire available-for-sale securities for fiscal 2017 was $88.31M, a 65.81% decline from fiscal 2016.
- Corvus Pharmaceuticals, Inc. payments to acquire available-for-sale securities for fiscal 2016 was $258.28M, a 147.43% increase from fiscal 2015.
- Corvus Pharmaceuticals, Inc. payments to acquire available-for-sale securities for fiscal 2015 was $104.39M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $13.24M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $41.24M derived: sum of 2 quarters · filed 2018-03-01 | $70.30M derived: sum of 3 quarters · filed 2018-03-01 | $88.31M 10-K · filed 2018-03-01 |
| 2017-09-30 | $28.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $57.06M derived: sum of 2 quarters · filed 2017-11-02 | $75.07M 10-Q · filed 2017-11-02 | $168.58M derived: sum of 4 quarters · filed 2018-03-01 |
| 2017-06-30 | $29.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $47.07M 10-Q · filed 2017-08-03 | $140.58M derived: sum of 3 quarters · filed 2018-03-01 | $152.56M derived: sum of 4 quarters · filed 2018-03-01 |
| 2017-03-31 | $18.01M 10-Q · filed 2017-05-04 | $111.52M derived: sum of 2 quarters · filed 2018-03-01 | $123.50M derived: sum of 3 quarters · filed 2018-03-01 | $185.16M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-12-31 | $93.51M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $105.49M derived: sum of 2 quarters · filed 2018-03-01 | $167.15M derived: sum of 3 quarters · filed 2018-03-01 | $258.28M 10-K · filed 2018-03-01 |
| 2016-09-30 | $11.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $73.64M derived: sum of 2 quarters · filed 2017-11-02 | $164.77M 10-Q · filed 2017-11-02 | $242.54M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $61.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $152.79M 10-Q · filed 2017-08-03 | $230.55M derived: sum of 3 quarters · filed 2018-03-01 | $231.45M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $91.13M 10-Q · filed 2017-05-04 | $168.90M derived: sum of 2 quarters · filed 2018-03-01 | $169.80M derived: sum of 3 quarters · filed 2018-03-01 | |
| 2015-12-31 | $77.76M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $78.66M derived: sum of 2 quarters · filed 2018-03-01 | $104.39M 10-K · filed 2018-03-01 | |
| 2015-09-30 | $900.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $26.62M 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | $25.72M 10-Q · filed 2016-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |